FNDC5 Inhibitors

FNDC5 inhibitors primarily target the signaling or the metabolic pathways associated with FNDC5 and its hormone product, irisin. Rosiglitazone, are PPARγ agonists known to influence adipogenesis, which can modulate the FNDC5/irisin levels. Conversely, GW9662, a PPARγ antagonist, offers an opposite mode of action that indirectly affects the FNDC5-related pathways. Given FNDC5's role in metabolism, compounds influencing metabolic pathways can have implications on its function. AICAR are examples that impact metabolic processes, potentially influencing FNDC5 activity.

Another layer of metabolic regulation involves the mTOR and AMPK pathways. Rapamycin, an mTOR inhibitor, has implications on FNDC5 signaling due to its profound effects on cellular metabolism. Similarly, AICAR, an AMPK activator, and Compound C, an AMPK inhibitor, can modulate metabolic processes intertwined with FNDC5. The importance of the PI3K pathway in insulin signaling and metabolism warrants the inclusion of PI3K inhibitors like Wortmannin and LY294002. Their potential influence on metabolic signaling could relate to FNDC5's action. Lastly, Metformin, widely known for its impact on AMPK and associated pathways, could play a role in FNDC5 modulation.